Michael Farzan

This paper describes a trimeric inhibitor, S22, that stabilizes the SARS-CoV-2 spike protein in a closed conformation, preventing ACE2 binding and viral entry.

The paper compares microglia-targeted AAVs, finding that capsid choice affects in vitro efficiency but not in vivo transduction when using specific promoters.

This study identifies SCARF2 as an intracellular receptor for HBV, showing it facilitates viral transport to the nucleus by binding preS1 and interacting with nuclear pore complexes.

The paper identifies variation in virion phosphatidylserine content as the reason for differential GAS6 binding among flaviviruses, explaining ZIKV's unique ability to use AXL for entry.

This paper develops a hydrogel depot system to prolong the release of broadly neutralizing antibodies, showing improved pharmacokinetics and reduced immune cell-mediated release through co-formulation with anti-inflammatory agents.

This study demonstrates that non-antibody protein biologics can undergo affinity maturation in vivo, leading to improved binding affinity and neutralization potency against HIV-1.

This study demonstrates that CRISPR-edited murine B cells expressing human antibodies can undergo affinity maturation, generating potent neutralizing antibodies against HIV-1 and SARS-CoV-2.